Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Castle Biosciences, Inc. stock logo
CSTL
Castle Biosciences
$15.97
+0.1%
$18.68
$15.45
$35.84
$461.09M1.19409,517 shs441,001 shs
National HealthCare Co. stock logo
NHC
National HealthCare
$104.14
-0.6%
$96.76
$89.14
$138.49
$1.61B0.5155,126 shs43,482 shs
PACS Group, Inc. stock logo
PACS
PACS Group
$9.93
$9.96
$8.28
$43.92
$1.51BN/A786,964 shs292,870 shs
Progyny, Inc. stock logo
PGNY
Progyny
$21.86
+2.4%
$22.09
$13.39
$30.42
$1.87B1.371.70 million shs1.13 million shs
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Castle Biosciences, Inc. stock logo
CSTL
Castle Biosciences
0.00%-0.81%-17.47%-24.92%-31.34%
National HealthCare Co. stock logo
NHC
National HealthCare
0.00%+1.77%+8.28%+11.52%-1.52%
PACS Group, Inc. stock logo
PACS
PACS Group
0.00%+1.43%-1.59%-24.31%-67.34%
Progyny, Inc. stock logo
PGNY
Progyny
0.00%+6.53%-5.90%-0.64%-18.89%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Castle Biosciences, Inc. stock logo
CSTL
Castle Biosciences
3.0603 of 5 stars
3.55.00.00.02.72.50.0
National HealthCare Co. stock logo
NHC
National HealthCare
N/AN/AN/AN/AN/AN/AN/AN/A
PACS Group, Inc. stock logo
PACS
PACS Group
3.727 of 5 stars
3.42.00.00.02.60.03.1
Progyny, Inc. stock logo
PGNY
Progyny
1.1001 of 5 stars
1.22.00.00.03.41.71.3
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Castle Biosciences, Inc. stock logo
CSTL
Castle Biosciences
3.00
Buy$37.00131.68% Upside
National HealthCare Co. stock logo
NHC
National HealthCare
0.00
N/AN/AN/A
PACS Group, Inc. stock logo
PACS
PACS Group
2.86
Moderate Buy$34.29245.27% Upside
Progyny, Inc. stock logo
PGNY
Progyny
2.42
Hold$23.457.29% Upside

Current Analyst Ratings Breakdown

Latest CSTL, PGNY, NHC, and PACS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/21/2025
Castle Biosciences, Inc. stock logo
CSTL
Castle Biosciences
Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetSector Outperform ➝ Sector Outperform$44.00 ➝ $40.00
5/12/2025
Progyny, Inc. stock logo
PGNY
Progyny
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetHold ➝ Hold$23.00 ➝ $21.00
5/6/2025
Castle Biosciences, Inc. stock logo
CSTL
Castle Biosciences
Lake Street Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$40.00 ➝ $35.00
5/6/2025
Castle Biosciences, Inc. stock logo
CSTL
Castle Biosciences
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$42.00 ➝ $37.00
3/31/2025
Progyny, Inc. stock logo
PGNY
Progyny
BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Buy$28.00
3/28/2025
Castle Biosciences, Inc. stock logo
CSTL
Castle Biosciences
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetBuy ➝ Buy$30.00
(Data available from 6/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Castle Biosciences, Inc. stock logo
CSTL
Castle Biosciences
$347.08M1.33N/AN/A$14.54 per share1.10
National HealthCare Co. stock logo
NHC
National HealthCare
$1.37B1.17$6.64 per share15.68$59.41 per share1.75
PACS Group, Inc. stock logo
PACS
PACS Group
$3.56B0.43N/AN/AN/A
Progyny, Inc. stock logo
PGNY
Progyny
$1.21B1.54$0.61 per share35.58$5.77 per share3.79
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Castle Biosciences, Inc. stock logo
CSTL
Castle Biosciences
-$57.47M-$0.1979.85N/AN/A1.95%1.47%1.27%8/4/2025 (Estimated)
National HealthCare Co. stock logo
NHC
National HealthCare
$66.80M$6.9213.05N/A10.03%6.87%4.68%N/A
PACS Group, Inc. stock logo
PACS
PACS Group
$112.87MN/A0.005.580.49N/AN/AN/AN/A
Progyny, Inc. stock logo
PGNY
Progyny
$62.04M$0.5737.6933.632.395.03%11.36%7.87%8/5/2025 (Estimated)

Latest CSTL, PGNY, NHC, and PACS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/8/2025Q1 2025
Progyny, Inc. stock logo
PGNY
Progyny
$0.45$0.17-$0.28$0.17$307.86 million$324.04 million
5/5/2025Q1 2025
Castle Biosciences, Inc. stock logo
CSTL
Castle Biosciences
-$0.08-$0.20-$0.12-$0.90$80.40 million$87.99 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Castle Biosciences, Inc. stock logo
CSTL
Castle Biosciences
N/AN/AN/AN/AN/A
National HealthCare Co. stock logo
NHC
National HealthCare
$2.562.46%+4.68%36.99%10 Years
PACS Group, Inc. stock logo
PACS
PACS Group
N/AN/AN/AN/AN/A
Progyny, Inc. stock logo
PGNY
Progyny
N/AN/AN/AN/AN/A

Latest CSTL, PGNY, NHC, and PACS Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
5/8/2025
National HealthCare Co. stock logo
NHC
National HealthCare
quarterly$0.642.7%6/30/20256/30/20258/1/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Castle Biosciences, Inc. stock logo
CSTL
Castle Biosciences
0.02
7.78
7.64
National HealthCare Co. stock logo
NHC
National HealthCare
0.14
1.80
1.77
PACS Group, Inc. stock logo
PACS
PACS Group
0.82
1.71
1.71
Progyny, Inc. stock logo
PGNY
Progyny
N/A
2.62
2.62

Institutional Ownership

CompanyInstitutional Ownership
Castle Biosciences, Inc. stock logo
CSTL
Castle Biosciences
92.60%
National HealthCare Co. stock logo
NHC
National HealthCare
56.44%
PACS Group, Inc. stock logo
PACS
PACS Group
N/A
Progyny, Inc. stock logo
PGNY
Progyny
94.93%

Insider Ownership

CompanyInsider Ownership
Castle Biosciences, Inc. stock logo
CSTL
Castle Biosciences
6.50%
National HealthCare Co. stock logo
NHC
National HealthCare
14.97%
PACS Group, Inc. stock logo
PACS
PACS Group
N/A
Progyny, Inc. stock logo
PGNY
Progyny
9.40%
CompanyEmployeesShares OutstandingFree FloatOptionable
Castle Biosciences, Inc. stock logo
CSTL
Castle Biosciences
54028.87 million25.99 millionOptionable
National HealthCare Co. stock logo
NHC
National HealthCare
12,40015.46 million13.32 millionN/A
PACS Group, Inc. stock logo
PACS
PACS Group
32,433152.40 millionN/AOptionable
Progyny, Inc. stock logo
PGNY
Progyny
31085.72 million74.68 millionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Castle Biosciences stock logo

Castle Biosciences NASDAQ:CSTL

$15.97 +0.02 (+0.13%)
Closing price 05/30/2025 04:00 PM Eastern
Extended Trading
$15.97 0.00 (0.00%)
As of 07:48 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Castle Biosciences, Inc., a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus. In addition, the company provides DecisionDx-UM test, a proprietary risk stratification GEP test that predicts the risk of metastasis for patients with uveal melanoma; and IDgenetix, a pharmacogenomic test that helps guide drug treatment for major depressive disorder, schizophrenia, bipolar disorder, anxiety disorders, social phobia, obsessive-compulsive personality disorder, post-traumatic stress disorder, and attention deficit hyperactivity disorder. It offers its products to skin cancer, gastroenterology, and mental health markets. The company was incorporated in 2007 and is headquartered in Friendswood, Texas.

National HealthCare stock logo

National HealthCare NYSE:NHC

$104.14 -0.58 (-0.55%)
As of 05/30/2025 04:00 PM Eastern

National HealthCare Corporation engages in the operation of services to skilled nursing facilities, assisted and independent living facilities, homecare and hospice agencies, and health hospitals. Its skilled nursing facilities offer licensed therapy services, nutrition services, social services, activities, and housekeeping and laundry services, as well as medical services prescribed by physicians; and rehabilitative services, such as physical, speech, respiratory, and occupational therapy for patients recovering from strokes, heart attacks, orthopedic conditions, neurological illnesses, or other illnesses, injuries, or disabilities. The company's medical specialty units comprise memory care units and sub-cute nursing units that provide specialized care and programs for persons with Alzheimer's or related disorders; and assisted living facilities offer personal care services and assistance with general activities of daily living, such as dressing, bathing, meal preparation, and medication management. Its independent living facilities offers specially designed residential units for the active and ambulatory elderly and provide various ancillary services for residents, including restaurants, activity rooms and social areas; and behavioral health services to both adults and geriatric patients with psychiatric, emotional, and addictive disorders. In addition, the company's homecare agencies assist those who wish to stay at home or in assisted living residences but still require some degree of medical care or assistance with daily activities; hospice agencies that provides hospice and palliative care; and operates pharmacies, as well as managed care insurance solutions. Further, it offers management, accounting, and financial services; and leases its properties to third party operators. The company was founded in 1971 and is based in Murfreesboro, Tennessee.

PACS Group stock logo

PACS Group NYSE:PACS

$9.93 0.00 (0.00%)
Closing price 05/30/2025 03:59 PM Eastern
Extended Trading
$9.92 -0.01 (-0.10%)
As of 08:17 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

PACS Group, Inc., through its subsidiaries, operates skilled nursing facilities and assisted living facilities in the United States. The company also provides senior care and independent facilities. It engages in the acquisition, ownership, and leasing of health care-related properties. The company was founded in 2013 and is based in Farmington, Utah.

Progyny stock logo

Progyny NASDAQ:PGNY

$21.86 +0.52 (+2.44%)
Closing price 05/30/2025 04:00 PM Eastern
Extended Trading
$21.50 -0.36 (-1.65%)
As of 08:18 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Progyny, Inc., a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists. The company also offers Progyny Rx, an integrated pharmacy benefits solution that provides its members with access to the medications needed during their treatment. In addition, it provides assistance service programs where various services can be offered through a reimbursement program, including adoption, surrogacy, doula, and travel reimbursement when travel is required to receive medical services. The company was formerly known as Auxogyn, Inc. and changed its name to Progyny, Inc. in 2015. Progyny, Inc. was incorporated in 2008 and is headquartered in New York, New York.